selected publications
- Do no harm: Distinguishing between rebound thymic hyperplasia and Hodgkin lymphoma relapse in children. Pediatric blood & cancer. 2023 Academic Article GET IT
- A Toddler With New Seizures, Progressive White Matter Lesions, and Multifocal Microhemorrhages. 2022 GET IT
-
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma.
Blood advances.
2021
Academic Article
GET IT
Times cited: 8 -
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.
Blood advances.
2021
Academic Article
GET IT
Times cited: 11 -
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders.
The Journal of allergy and clinical immunology.
2021
Academic Article
GET IT
Times cited: 4 -
Langerhans cell histiocytosis: Version 2021.
Hematological oncology.
2021
Review
GET IT
Times cited: 16 - Differential Impact of ALK Mutations in Neuroblastoma. JCO precision oncology. 2021 Academic Article GET IT
-
Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.
Cancers.
2020
Academic Article
GET IT
Times cited: 19 -
Endoscopic ultrasound-guided diagnosis of Helicobacter pylori-associated gastric Burkitt's lymphoma in an adolescent patient: a rare case.
2020
GET IT
Times cited: 1 -
Sleep in Hospitalized Children With Cancer: A Cross-Sectional Study.
Hospital pediatrics.
2020
Academic Article
GET IT
Times cited: 9 -
The global challenge of treating disseminated LCH.
Pediatric hematology and oncology.
2020
Academic Article
GET IT
Times cited: 1 -
ALPS or not?.
Blood.
2020
Comment
GET IT
Times cited: 4 -
Perceptions of Insulin Pen Use and Technique in Black and Hispanic/Latino Patients with Type 2 Diabetes: a Qualitative Study.
Journal of racial and ethnic health disparities.
2020
Academic Article
GET IT
Times cited: 3 -
Enhancer of zeste homolog 2 (EZH2) inhibitors.
Leukemia & lymphoma.
2018
Review
GET IT
Times cited: 114